Pulmonx Corp Cash Flow Statement
LUNG|6 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Pulmonx Corp used $32M in operating cash flow and negative free cash flow of $33M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.54 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | -$56.4M | -$60.8M | -$58.9M | -$48.7M | -$32.2M | -$18.5M |
| Depreciation & Amortization | $1.1M | $1.4M | $1.4M | $700.0K | $300.0K | $100.0K |
| Operating Cash Flow | -$31.5M | -$37.6M | -$45.1M | -$41.4M | -$30.6M | -$18.4M |
| Capital Expenditures | $1.4M | $807.0K | $1.3M | $3.7M | $911.0K | $316.0K |
| Free Cash Flow | -$33.0M | -$38.4M | -$46.4M | -$45.1M | -$31.5M | -$18.7M |
| Share Buybacks | - | - | $27.0K | $26.0K | $21.0K | $0 |
| FCF Margin | -39.4% | -55.9% | -86.5% | -93.1% | -96.4% | -93.5% |